Document:

<PAGE>

                                                                    Exhibit 4.10

                           MANAGING DIRECTOR AGREEMENT

                                 by and between

           DIAGEN Institute for Molecular Biological Diagnostics GmbH,
                        Eichenwand 15, 4000 Dusseldorf 12
                      Represented by the Board of Directors

                        - hereinafter DIAGEN or Company-

                                       and

                                Dr. Metin Colpan

                        - hereinafter Managing Director -

The following managing director agreement is concluded between the parties
effective July 7, 1985:

                                    Article 1
                           Function and Authorization

(1)  Dr. Colpan shall assume the responsibility of Managing Director based on
     the November 29, 1984 resolution. The rights and obligations of Dr. Colpan
     as Managing Director of DIAGEN are determined in accordance with this
     agreement by the company agreement, supplementary legal regulations and
     company rules and regulations.

     (2)  Dr. Colpan shall represent the company in cooperation with another
          Managing Director or Proxy. He is, to the extent simultaneously a
          Partner and Managing Director, released form the restrictions of
          self-dealing according to (S) 181 BGB.

     (3)  Dr. Colpan is obligated to follow the instructions of the
          Shareholders' Meeting and Board of Directors. This applies to general
          regulations with regard to managing the company as well as to the
          Company Rules and Regulations which indicates the boundaries of
          management authority and responsibility as well as the list of

<PAGE>

     activities needing the approval provided in the latest effective version of
     the Shareholder Agreement including any prospective changes to it.

                                    Article 2
                         Job Description and Management

(1)  The activities incumbent upon Dr. Colpan shall be those assigned by
     organizational chart according to resolution of the Board of Directors. He
     performs his responsibilities in cooperation with another Managing
     Director. This applies especially in the case of such business which must
     be submitted to all of the Directors for approval in accordance with the
     Company Rules and Regulations.

(2)  Dr. Colpan shall manage the company with the care and prudence of an
     ordinary business man and perform the tasks assigned to him during his
     activities conscientiously and to the best of his abilities, to safeguard
     and promote the employer's interests in every respect and to dedicate all
     his activities and their consequences to exclusively to DIAGEN, to the
     extent not expressly determined otherwise by the company. Ancillary
     employment - also advisory, expert or of a similar nature -, such as the
     acceptance of positions on advisory committees, supervisory boards, boards
     of directors, chambers of commerce and other committee associations, etc.,
     shall only be permissible if express prior consent may be obtained from the
     Supervisory Board.

(3)  Dr. Colpan shall inform his Co-Managing Director and the Supervisory Board,
     if necessary, about all activities which may be of interest. The above
     applies also to observations and information outside of his own direct area
     of responsibility.

                                    Article 3
                           Trade and Business Secrets

(1)  Dr. Colpan is obligated to maintain total and absolute secrecy on all
     confidential matters and activities, in particular on business and
     operational secrets, that he obtains knowledge of within the framework of
     his activities during his employment as well as after his leaving the
     employment relationship including knowledge of program systems, company and
     operating equipment and procedures, production and sales figures for the
     group of associated companies, especially with respect to customer lists,
     marketing plans, business documents, sketches, specifications, methods,
     process techniques, business practices, formulas, business, personal and
     financial data, data base, product/ processing specifications and drawings,
     test ledgers and instructions, internal reports, planned research
     initiatives, recycling plans, public funding, and all other documents and
     information related to the conditions of the company, associated companies
     and persons, business partners, employees and similar persons. The secrecy
     obligation shall also apply to physical objects, especially designs, and
     includes the obligation not to publish or share such information and
     prevent the publishing or sharing of such information by other persons. The
     obligations shall not be applicable to the extent that such information

<PAGE>

     has been or shall be published without the knowledge and consent of Dr.
     Colpan or to the extent that exchange of information or materials with
     third parties seems well understood to be in the interest of the company.
     The obligation of secrecy extend beyond the parameters of the contractual
     relationship. It is applicable not only in relationship to any external
     third parties but also DIAGEN employees and subcontractors to the extent
     the latter are not unquestionably authorized to receive such information by
     way of their official activities.

(2)  The special regulations defining penalties for violation of business and
     trade secrets according to (S)17 of the law against unfair competition are
     familiar to Dr. Colpan.

                                    Article 4
                   Operating Results and Creative Developments

(1)  Rights to inventions or other technical improvements which Dr. Colpan
     develops or acquires during his employment as Managing Director of the
     company or in connection with his activities for the company belong to the
     company. Dr. Colpan shall with this agreement assign all corresponding
     rights to DIAGEN.

(2)  The company is in this regard not obligated to provide any additional
     compensation. The law on employer rights in employee inventions is not
     applicable since Dr. Colpan's activities do not fall within the definitions
     of employee.

(3)  Dr. Colpan shall assign DIAGEN the exclusive use of all patented rights in
     his possession whether in connection with his current activities, based on
     his prior experience and employment with the company or produced by the
     company itself.

(4)  Dr. Colpan is obligated to offer DIAGEN the use of any inventions or
     technical improvements he has developed not included in the Article 1
     description. If DIAGEN chooses to use these inventions or technical
     improvements, Dr. Colpan shall receive appropriate compensation.

(5)  Dr. Colpan promises to keep the company informed of details in connection
     with inventions, technical improvements, and gained independent know-how
     with regard to the meaning of patentable and non-patentable inventions
     improvements, etc., for example, knowledge obtained through conversations
     with experts.

                                    Article 5
                             Anti-Competition Clause

(1)  For the duration of this agreement, Dr. Colpan is not permitted to engage
     in activities for a company resembling the DIAGEN Group or which could
     potentially compete with the DIAGEN Group either on his own or for a
     third-party, independently or dependently. This prohibition applies to any
     activity including advising or promoting such a company in another way,
     notwithstanding whether the activity is performed temporarily or only
     occasionally.

<PAGE>

This above described anti-competition clause applies in Germany and extends
beyond the termination of the contractual relationship for a period of one year.
To the extent the effectiveness of competing offers shall be dependent on
payment of compensation, DIAGEN promises to pay the legally defined minimum
compensation according to legal regulations and jurisdictional principles. Dr.
Colpan is, in the case of mandatory compensation, obligated to communicate
information relating to which company he is engaged by and the amount of
compensation received. DIAGEN shall be permitted to withdraw this
post-contractual anti-competition clause at any time prior to the ending of this
agreement in writing.

                                    Article 6
                                  Compensation

(1)  Dr. Colpan shall be compensated for his activities by a fixed annual gross
     amount of DM 104,000.-- payable in accordance with legally prescribed
     deductions in 12 monthly equal amounts of DM 8,000.-- retroactively at the
     end of every month and a 13th salary in the amount of DM 8,000.--with the
     November salary. In addition to the annual gross salary, Dr. Colpan shall
     receive holiday pay in the amount of 25% of the gross monthly salary
     consequently at the moment DM 2,000.--.

(2)  Furthermore, Dr. Colpan shall be entitled to receive an appropriate,
     results-contingent share of profits, the amount of which shall be
     recommended by the Board of Directors during its approval of the annual
     report. The bonus shall be received within two weeks of Board Approval.

(3)  According to the provisions on compensation according to Articles 6.1 and
     6.2, the entire Managing Director activity by Dr. Colpan including
     responsibility for subsidiaries, participating investments or other
     companies. To the extent that Dr. Colpan receives direct compensation for
     such mandate from the companies concerned, shall this compensation be
     treated in accordance with this agreement and charged to the bonus to the
     extent not agreed otherwise.

(4)  If Dr. Colpan is prevented from performing his duties because of disability
     due to illness or accident that is not his fault, he shall not lose his
     claim to fixed compensation for the period of his inability to work up to
     the end of the sixth full month following the onset of his inability to
     work. Third party payments such as shall be received from liability claims,
     health insurance, etc. shall be used by the company to make up the net
     salary Dr. Colpan would have received should he have been able to work.

                                    Article 7
                      Other Compensation and Reimbursement

<PAGE>

(1)  The Employee will be provided with a midrange business vehicle which he may
     also use for private use. The monetary value of private vehicle use subject
     to income tax in conformity with tax regulations and chargeable to the
     Employee is taken into account in the payment of remuneration indicated in
     Article 6.1.

(2)  DIAGEN shall include Dr. Colpan in the existing group accident insurance
     which cover all risks of accidents, also those apart from the workplace.
     The insurance amount in the event of death shall be DM 50,000.00, in the
     event of disability, DM 200,000.00. Beneficiary from the insurance shall be
     Dr. Colpan or the person he designates. The insurance premium shall be
     treated as compensation according to 6.1 above and so allocated.

(3)  Lodging and travel expenses including the costs of overnight stays and
     other expenditures in the interests of the company shall be reimbursed to
     Dr. Colpan within appropriate limits. Guidelines for reimbursement claims
     shall be explicitly followed in the case that expenditures related to
     publicly subsidized projects. The expenditures shall be individually
     documented according to tax requirements to the extent not deducted as a
     lump sum for tax purposes.

                                    Article 8
                                    Vacation

(1)  Dr. Colpan shall be entitled to an annual vacation of 25 workdays.

(2)  Vacation date shall be determined in consultation with the Co-Managing
     Director, if needed with the assistance of the Chairman of the Board of
     Directors, demonstrating appropriate consideration for the functional
     concerns of the company.

(3)  Any vacation not taken shall be forfeited on March 31 of the subsequent
     year. A claim for compensation may not be rendered legal enforceable on
     fundamental grounds.

                                    Article 9
              Duration and Termination of the Employment Agreement

(1)  The employment agreement is concluded for an indeterminate time period and
     enters into effect on July 1, 1985.

(2)  The employment agreement may be terminated by either party at the end of
     each calendar half-year, with six months notice, at the earliest, however,
     June 30, 1990. In cases of doubt, termination as Managing Director serves
     simultaneously as termination of the Managing Director Agreement at the
     next possible date. Termination shall be communicated by registered letter.
     The company shall be represented by the Board of Directors in the case of
     termination notwithstanding which party has initiated the request unless
     not legally permissible.

<PAGE>

(3)  The right to terminate this agreement for serious cause shall remain
     unaffected. An important reason for the company is represented by violation
     of essential provisions of the agreement or of restrictions imposed on
     inner relations or if the Managing Director leaves prior to March 31, 1990.

(4)  The employment relationship shall end without notice at the expiration of
     the month in which Dr. Colpan reaches age 65, or in case of a prolonged
     inability to work which shall be conclusively determined through medical
     evaluation performed by a doctor which the company selects.

                                   Article 10
                                   Termination

(1)  In the case of termination of the contractual relationship, Dr. Colpan
     shall be released from his responsibilities under the terms of this
     agreement independent of the effectiveness of the termination subject to
     the satisfying of other commitments and his legal rights.

(2)  At the time of termination of the agreement, in the case of release at this
     date, Dr. Colpan shall return business and personal documents related to
     operating procedures of DIAGEN or associated companies, other materials
     including photocopies, duplicates, extracts, as well as any other types of
     copies or recorded information without needing to be requested by the
     company; all documents related to the company no matter what format remain
     sole possession of the company. With regard to a business vehicle provided
     by the company, at any time between notice of termination and expiration of
     the agreement, the company may decide upon return of the vehicle with
     appropriate financial remuneration to be made to compensate the loss of
     private vehicle use.

(3)  At the request of the company, as soon as notice of termination has been
     communicated, Dr. Colpan is obligated to cease all mandates for which he is
     responsible in his capacity as Managing Director or in connection with this
     post irrespective of which party has submitted the request for termination
     of the employment relationship.

(4)  Dr. Colpan expressly promises to undertake neither direct nor indirect
     patent registration without offering the company use of the respective
     discovery for the duration of the employment agreement through its
     termination. The company promises on its part to maintain strict
     confidentiality with regard to any communication from Dr. Colpan about such
     a discovery, to indemnify Dr. Colpan against any damages, particularly in
     the event that DIAGEN does not use the discovery, and in the event of use,
     to grant compensation the amount of which shall be dependent upon in what
     measure the discovery has been based on the preceding activity of DIAGEN.

<PAGE>

                                   Article 11
                               Contractual Penalty

     A serious violation of the agreement by Dr. Colpan, especially against the
     obligations of secrecy, anti-competition clause, requirement to return all
     documents by termination of the agreement or the promise to communicate the
     news of inventions and offer use, etc., also after termination of this
     agreement, Dr. Colpan shall have to pay a contractual penalty in the amount
     of one quarter of his annual salary. The contractual penalty shall be
     incurred at each case of violation. Payment of this penalty is due
     immediately exclusive of any offset, retention or denial of services on the
     part of the Managing Director.

(2)  The right to assert further damages in the case that penalties have not
     fully reflected damages incurred by the company or shareholders remains
     unaffected.

                                   Article 12
                                Final Provisions

(1)  This agreement contains all agreements between the parties. The parties
     have concluded no other agreements with the exception of the ones set forth
     above. Any amendments to the agreement shall be in writing.

(2)  Dr. Colpan declares that he is aware of no grounds for which this agreement
     shall not be concluded.

(3)  Place of performance and legal court of jurisdiction in any dispute arising
     from this agreements shall be that of the corporate headquarters. To the
     extent legally permissible, the court of arbitration agreement applies to
     any dispute concluded between the company and all shareholders in
     connection with this Managing Director Agreement

(4)  If any provision of this contract should be or become ineffective, the
     legal validity of the remaining provisions shall not be affected thereby.
     In lieu of the invalid provision, the parties agree to concur on a
     provision that comes the closest, in economic terms, to the invalid one.
     The same shall apply in the event of a loophole, or if any individual
     provisions should be or become impracticable.

Dusseldorf, August 30, 1985

DIAGEN Institute for Molecular Biological Diagnostics
For the Board of Directors:

By: /s/ D. Riesner
    ------------
Chairman of the Supervisory Board

Employee

/s/ Metin Colpan
----------------
Metin Colpan<PAGE>

                                                                    Exhibit 4.11

                              EMPLOYMENT AGREEMENT

                                 by and between

          DIAGEN Institute for Molecular Biological Diagnostics, GmbH,
                         Max-Volmer-Str. 4, 4010 Hilden

                             - hereinafter DIAGEN -

                                       and

                               Mr. Peer M. Schatz

                            - hereinafter Employee -

                                    Article 1
                   Commencement of the Employment Relationship

(1)  The Employee shall commence his activities on January 5, 1993.

(2)  The initial six months shall be deemed as a probationary period. During
     said probationary period, one month's notice of termination may be given by
     either party at the end of any month.

                                    Article 2
                                 Job Description

(1)  The Employee shall assume the responsibilities of Director, Finance,
     Accounting and Controlling. He shall perform all tasks in conjunction with
     the aforementioned activities.

(2)  The Employee shall report to the Executive Board.

(3)  The Company reserves the right to assign to the Employee a different field
     of tasks that corresponds to his education and his abilities with his
     remuneration remaining unchanged.

<PAGE>

(4)  The right of termination due to a change of contract shall remain
     unaffected.

                                    Article 3
                                 Work Deployment

(1)  The Employee's weekly work period shall comprise 39 hours.

(2)  The Employee agrees to perform the tasks assigned to him during his
     activities conscientiously and to be best of his abilities, and to
     safeguard DIAGEN's interests in every respect. The Employee agrees in
     particular to comply with all legal and corporate safety regulations.

(3)  The Employee shall be ready and willing to work overtime and extra hours
     within the framework of operational requirements.

                                    Article 4
                        Ancillary Activities and Lectures

(1)  Any independent or task-related ancillary activity by the Employee shall
     require the prior written approval of DIAGEN. DIAGEN shall grant such
     approval if the ancillary activity does not violate DIAGEN's interests.

(2)  Lectures and publications shall also require approval of DIAGEN if DIAGEN's
     interests are touched. The subject and relevant content shall be reviewed
     by a Superior for his approval.

                                    Article 5
                                     Salary

(1)  The Employee shall receive a gross monthly salary of DM 10,000.

(2)  In addition, the Employee shall receive benefits in the form of
     contributions to an Employee stock investment plan in the gross amount of
     DM 52.00 per month.

(4)  The salary including any supplemental bonuses, etc. shall be transferred in
     non-cash form at the end of each month to an account to be named by the
     Employee.

(5)  The aforementioned base pay explicitly includes any remuneration for extra
     or overtime work.

                                    Article 6
                                  Vacation Pay

(1)  The Employee shall receive voluntary vacation pay together with his June
     salary in the amount of DM 30.00 per vacation day as set forth in Article
     12; such pay shall be

<PAGE>

     revocable at any time. In the entry year, the Employee vacation pay shall
     be prorated.

                                    Article 7
                               Christmas Gratuity

(1)  Together with the November salary, the Employee shall receive a Christmas
     bonus in the amount of one fixed salary pursuant to Article 5 (1).

(2)  No claim to the Christmas gratuity shall exist if the employment agreement
     is terminated by either party at the time of disbursement or as per
     December 31 of any year, or if it ends pursuant to an agreement to
     terminate the contract. However, this shall not apply if the termination
     occurs for personal reasons that the Employee does not need to justify. The
     same shall apply to any agreement to terminate the contract.

(3)  The Employee shall repay the Christmas gratuity if he leaves of his own
     volition, through extraordinary termination by DIAGEN or for reasons of
     misconduct by March 31 of the calendar year following the disbursement or
     in the event that the Christmas gratuity amounts to more than one month's
     remuneration, if he leaves by June 30 of the calendar year following the
     disbursement.

(4)  The repayment obligation set forth above shall be in force also in the
     event that the employment agreement is terminated within the aforementioned
     period by way of an agreement to terminate the contract and if the
     agreement to terminate the contract is in lieu of an extraordinary
     termination or termination based on misconduct and issued within the
     prescribed time limits or if it is due to a termination request on the part
     of the Employee.

(5)  In the entry year, the Christmas bonus shall be prorated.

                                    Article 8
                         Salary Pledge and/or Assignment

(1)  The Employee may pledge or assign his remuneration claims to any third
     parties only with the prior approval of DIAGEN.

(2)  The Employee shall bear the actual costs of the pledge, if granted, in an
     amount not less than DM 10.00 per payment to the pledge creditor.

                                    Article 9
                                 Travel Expenses

(1)  For travel in the interest of DIAGEN, the EMPLOYEE shall be entitled to
     reimbursement of costs in accordance with the following provisions:

<PAGE>

(2)  In general, expenditures must be within appropriate levels. The guidelines
     established by the Employer must be observed as well as the following
     provisions:

(3)  In the event of an overnight stay, the costs of a four star hotel shall be
     reimbursed. Second class train fares and economy class flights shall be
     reimbursed. Taxi, telephone and fax expenses shall be reimbursed in their
     actual amounts.

(4)  Additional expenditures for business entertainment, food and related
     expenses shall be included in the taxable lump sum amount.

(5)  Expenditures shall be reimbursed in their actual amounts only when
     documented by receipts.

(6)  Invoicing of expenditures shall be made at the end of the month.

(7)  The Employee shall be entitled to an appropriate advance of these sums to
     the extent needed.

                                   Article 10
                                    Insurance

(1)  DIAGEN shall include the Employee in the existing group accident insurance.
     The insurance amount in the event of death shall be DM 50,000.00, in the
     event of disability, DM 200,000.00.

(2)  Beneficiary from the insurance shall be the Employee in the event of
     disability; in the event of death, the person designated by the Employee.
     If no person has been designated, the beneficiary shall be the spouse,
     otherwise the other legal heirs.

                                   Article 11
                               Employee Inventions

The law on employee inventions shall be applicable, as well as the guidelines
issued thereto on the remuneration of employee inventions in private service.

                                   Article 12
                               Secrecy Obligation

(1)  The Employee agrees to maintain secrecy on all confidential matters and
     activities, in particular on business and operational secrets, that he
     gains knowledge of within the framework of his activities during his
     employment as well as after his leaving the employment relationship. The
     secrecy obligation shall also apply to the salary agreement as concluded.

<PAGE>

(2)  The aforementioned secrecy obligation shall not only apply vis-a-vis any
     external third parties but also vis-a-vis other Employees of DIAGEN to the
     extent that the latter are not authorized to receive such information by
     way of their official activities.

                                   Article 13
                        Obligation to Provide Information

The Employee will inform his superiors and the management also, if necessary,
about all activities in his area of responsibility, to the extent that this
knowledge is of importance to superiors, e.g. in order to avoid damages or carry
out improvements. The above applies also to observations and information outside
of his own direct area of responsibility.

                                   Article 14
                                    Vacation

(1)  DIAGEN shall grant the Employee 5 weeks (25 workdays) of vacation.

(2)  The vacation claim shall increase by one workday for each full year of
     service, up to a maximum of 30 workdays.

(3)  The vacation shall be coordinated with his/her superior and the [other]
     employees.

(4)  The Employee shall provide DIAGEN with his/her vacation address.

(5)  Any vacation not taken shall be forfeited on March 31 of the subsequent
     year.

                                   Article 15
                                Inability to Work

(1)  The Employee is required to notify DIAGEN without delay of any inability to
     work, in particular of any disability and its anticipated duration. Upon
     request, the reasons for the inability to work shall be disclosed. In the
     event of any deadlines, the Employee shall point out any work requiring
     preferential attention.

(2)  If the inability to work lasts longer than 3 calendar days, the Employee
     shall submit a doctor's attestation of the existence of the inability to
     work as well as its anticipated duration not later than on the following
     workday.

(3)  If the Employee is prevented from performing his duties because of
     disability due to illness that is not his fault, he shall not lose his
     claim to compensation for the period of his inability to work up to a
     period of 6 weeks.

<PAGE>

(4)  In the event of approval of a recuperative, rehabilitative or other health
     measure, the employee shall present an attestation without delay regarding
     the approval and duration of treatment as well as any other relevant
     information.

                                   Article 16
                                   Assignment

(1)  Claims for damages from any third party due to loss of wages incurred by
     him because of the Employee's inability to work shall be transferred to
     DIAGEN to the extent that DIAGEN has continued to pay the Employee's
     remuneration.

(2)  The Employee shall provide QIAGEN without delay with any information
     necessary for the assertion of such damage claims.

                                   Article 17
                      Duration of the Employment Agreement

(1)  The employment agreement is concluded for an indeterminate time period.

(2)  After the probation period, the employment agreement may be terminated at
     the end of any quarter, with six weeks notice. After one year, the period
     of notice shall be extended to 3 months of any quarter. The period for
     providing notice shall be extended in accordance with the legal provisions.
     Any extension of the period of notice for the Employer shall be matched in
     equal time by an extension of the period of notice on the part of the
     Employee.

(3)  Any termination shall have to be given in writing. Transmission of a signed
     fax shall be deemed to be in compliance with the written requirement.

(4)  DIAGEN shall have the right to release the Employee after notice has been
     given, honoring any residual vacation claims.

(5)  At the latest, the employment agreement shall end with the expiration of
     the month in which the Employee reaches age 65. The EMPLOYEE is obligated
     to confirm this agreement providing sufficient notice prior to this date.

(5)  The right to terminate without notice shall remain unaffected. Any
     termination without notice shall at the same time be deemed a precautionary
     termination given within the legally prescribed time limits.

                                   Article 18
                               Contractual Penalty

If in violation of the agreement, the Employee does not commence his activities,
terminates them prematurely, is terminated without notice, or violates the
secrecy

<PAGE>

obligations set forth in Article 12, he shall have to pay a contractual penalty
in the amount of one gross monthly salary pursuant to Article 5. DIAGEN shall
have the right to assert further damages.

                                   Article 19
                           Return of Business Records

(1)  All business and work records regardless of their nature, including
     data-processing programs and the like, shall remain the property of the
     Company. Removal from the business premises shall be permitted only with
     the approval of superiors.

(2)  The business records, and likewise any copies, duplicates, etc., must be
     returned at any time upon request, or at the time of termination of the
     employment relationship.

(3)  The Employee shall have no right of retention.

                                   Article 20
                                 Expiration Date

All claims arising from this employment relationship shall be forfeited unless
they are asserted in writing not later than six months following their coming
into being and, in the event they are refused by the other party, unless they
are asserted in court within two months after communication of the refusal.

                                   Article 21
                                Final Provisions

(1)  The parties have concluded no other agreements with the exception of the
     ones set forth above.

(2)  Any future amendments of and/or supplements to the agreement shall be in
     writing in order to acquire legal effect. This shall apply to the preceding
     sentence as well.

(3)  If any provision of this contract should be or become ineffective, the
     legal validity of the remaining provisions shall not be affected thereby.
     In lieu of the invalid provision, the parties agree to concur on a
     provision that comes the closest, in economic terms, to the invalid one.
     The same shall apply in the event of a loophole, or if any individual
     provisions should be or become impracticable.

Hilden, February 24, 1993

DIAGEN
Institute for Molecular Biological Diagnostics, GmbH

<PAGE>

By: /s/ Dr. Metin Colpan                    By: /s/ Dr. Jurgen Schumacher
   ---------------------                        -------------------------
Dr. Metin Colpan                            Dr. Jurgen Schumacher

Employee

/s/ Peer M. Schatz
------------------
Peer M. Schatz

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00049-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00049-of-00352.parquet"}]]